POMES Syndrome Clinical Trial
Official title:
A Phase I Clinical Trial of Human CD19/BCMA Bispecific CAR-T Cell Therapy for Subjects With Relapsed and Refractory POMES Syndrome.
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.
Primary Objectives 1. To determine the feasibility ad safety of anti-CD19/BCMA CAR-T cells in treating patients with relapsed and refractory POMES Syndrome. Secondary Objectives 1. To access the efficacy of anti-CD19/BCMA CAR-T cells in patients with POMES Syndrome. 2. To determine in vivo dynamics and persistency of anti-CD19/BCMA CAR-T cells. ;